Candidate for validation | Gene | C9-ALS versus C9-FTD | C9-ALS versus CAR | C9-FTD versus CAR |
Chitinase-3-like protein 2 | CHI3L2 | ↑ | ↑↑ | ↑ |
Neural cell adhesion molecule L1-like protein | CHL1 | ↑ | ns | ↓ |
Alpha-crystallin B chain | CRYAB | ↑↑ | ↑↑ | ns |
Neural proliferation differentiation and control protein 1 | NPDC1 | ↑ | ns | ↓ |
Neuronal pentraxin receptor | NPTXR | ↑ | ns | ↓ |
Profilin-1 | PFN1 | ↑ | ↑ | ns |
Transferrin receptor protein 1 | TFRC | ↑ | ↑ | ns |
Triggering receptor expressed on myeloid cells 2 | TREM2 | ↑ | ↑↑ | ns |
Thioredoxin domain-containing protein 17 | TXNDC17 | ↑ | ↑ | ns |
Ubiquitin carboxyl-terminal hydrolase isozyme L1 | UCHL1 | ↑ | ↑ | ns |
Neurosecretory protein VGF | VGF | ↑ | ns | ↓ |
↑/↓significant upregulation or downregulation; ↑↑: at least twofold significant upregulation.
C9-ALS, amyotrophic lateral sclerosis patients with C9orf72 hexanucleotide repeat expansion; CAR, asymptomatic C9orf72 hexanucleotide repeat expansion carriers; C9-FTD, frontotemporal dementia patients with C9orf72 hexanucleotide repeat expansion; iTRAQ, isobaric tags for relative and absolute quantitation; ns, not significant.